Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will.
– Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 –
– Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23 – Increased FY 2024 revenue.
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon.